PSI ToxSIG Webinar: Beyond the looking glass - Interpreting animal welfare & behaviour by monitoring & assessing mice activity data
Analysing continuously collected locomotive activity data to interpret mice welfare and behaviour.
For our first joint event with the RSS, Abdus Wahed and Nicola Schmitt joined us to present their work on survival analysis.
Joint PSI Pharmaceutical Statistics & Royal Statistical Society (RSS)
Audio Recordings
Webcast
CHAIR: James Carpenter, LSHTM
Royal Statistical Society (RSS)
Speaker: Abdus S. Wahed, University of Pittsburgh
Evaluating joint effects of induction–salvage treatment regimes on overall survival in acute leukaemia
Co-author: Peter F. Thall;
Journal of the Royal Statistical Society: Series C (Applied Statistics), Volume 62, Issue 1, Pages 67–83, January 2013
Abstract | Paper+ | Slides
Statisticians in the Pharmaceutical Industry (PSI)
Speaker: Nicola Schmitt, AstraZeneca
Attenuation of treatment effect due to measurement variability in assessment of progression-free survival
Co-authors: S. Hong, A. Stone, J. Denne
Pharmaceutical Statistics, Volume 11, Issue 5, pages 394-402, September/October 2012
Abstract | Paper+ | Slides
Analysing continuously collected locomotive activity data to interpret mice welfare and behaviour.
Our next journal club features two papers on the topic of Survival Analysis. For each of these published papers there will be a 20 minute presentation by author followed by a 10 minute discussion.
The field of data visualization is the intersection of data journalism, statistics, graphic design, computer science, neuroscience, and cognitive psychology. We will focus on the latter two fields of data visualization as it relates to data visualization: neuroscience and cognitive psychology.
Hear about potential strategies to handle non-proportional hazards and delayed treatment effects from experts in the field.
As a statistician in the Biostatistics and Programming Department, you will be responsible for the methodological and statistical aspects of projects in early clinical development in order to optimize the early development plan and ensure its coherence.
By joining our company, in this role you will apply your skills and experience in support of developing scientifically based arguments aiming to provide fair accessibility to our company’s drugs and vaccines making a real difference in patient’s lives.
As a Director of Statistics, you will be accountable for guiding statisticians in their work, performing senior review of documentation and output deliveries, providing oversight and advising on best practices approach to statistics for clinical trials.